Active	Status	Sponsor type	Region	Phase	Filter
3 Active 1 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Litwin, Sheldon E
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES)	Recruiting	3	10000	Europe, Canada, US, RoW	Retatrutide, LY3437943, Placebo	Eli Lilly and Company	Overweight and Obesity	02/29	02/29
SUMMIT, NCT04847557: A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The Trial	Active, not recruiting	3	731	US, RoW	Tirzepatide, LY3298176, Placebo	Eli Lilly and Company	Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)	06/24	07/24
Rebalance-HF, NCT04592445: Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF	Recruiting	N/A	80	US	Satera GSN Ablation, Sham Control	Axon Therapies, Inc.	Heart Failure With Preserved Ejection Fraction	04/22	03/23